Lepu Biopharma Co. Ltd. Class H
HHKEX:21573.75
HKD
-0.43
(-10.29%)
ISIN
CNE100004SM4
Return %
Stock
S&P 500
1Y
-42.22
14.20
3Y
0.00
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Ziye Sui
- Full Time Employees
- 710
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Block 4 Shanghai SH China 201612
- IPO Date
- Feb 23, 2022
- Website
- lepubiopharma.com
- Similar Companies
- Business
- Lepu Biopharma Co., Ltd. (2157.HK) is a China-based biopharmaceutical company focused on the discovery, development, and commercialization of oncology therapeutics, including antibody-drug conjugates (ADCs), oncolytic virus drugs, and immunotherapies. Founded in 2018 and headquartered in Shanghai, the company operates primarily in China with a global vision, advancing pipelines through clinical and pre-clinical stages for tumor treatments targeting unmet medical needs in cancer patients. Its core products and services encompass two commercial-stage products; eight clinical-stage candidates, six of which are ADCs such as MRG003 (EGFR-targeted), MRG002 (HER2-targeted), MRG004A (TF-targeted), and CMG901 (CLDN18.2-targeted); oncolytic virus therapies like LP002; immunotherapies including HX008; and three clinical-stage combination therapies, supported by an integrated ADC technology platform covering drug discovery, clinical development, CMC, and GMP-compliant manufacturing. The company serves domestic and international markets, with products sold at home and abroad, and maintains key pipeline assets like MRG003, MRG002, HX008, and LP002 in advanced development. In recent developments, Lepu Biopharma entered into an exclusive global licensing agreement with ArriVent BioPharma in January 2025 for ARR-217 (MRG007), an ADC targeting gastrointestinal cancers, granting ArriVent rights outside Greater China. It also partnered with BioDlink and Chime Biologics for commercial production advancements, including the world's first EGFR-targeted ADC launch, and licensed CMG901 to AstraZeneca via joint venture KYM in 2023, recognizing milestone payments in 2024; additionally, in 2025, it completed a licensing transaction and Series A fundraising for Excalipoint Cayman to globalize pipelines while prioritizing next-generation ADCs and IO bi/tri-specific antibodies.